Drug for Cystic Fibrosis is under clinical development by Zambon Co and currently in Phase III for Cystic Fibrosis. According to GlobalData, Phase III drugs for Cystic Fibrosis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Drug for Cystic Fibrosis’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Drug for Cystic Fibrosis overview

Drug candidate is under development for the treatment of cystic fibrosis.

Zambon Co overview

Zambon Co (Zambon) manufactures pharmaceutical and fine chemical products. The company offers pharmaceutical products for the respiratory, central nervous system, pain management, women’s healthcare, and rare diseases and specialties, including Parkinson’s disease and cystic fibrosis. It also provides active pharmaceutical ingredients (API), intermediates and custom synthesis services. The company has manufacturing plants in Cadempino, Switzerland; Haikou, China; Vicenza, Italy; and Barueri, Brazil. It distributes products directly and also through a network of distributors across North America, Latin America, Europe, the Middle East, and Africa, and Asia. Zambon is headquartered in Milano, Italy.

For a complete picture of Drug for Cystic Fibrosis’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.